We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04443192
Recruitment Status : Terminated (Based on the results observed to date, the Sponsor concluded that ZF874 was unlikely to achieve the desired target product profile.)
First Posted : June 23, 2020
Last Update Posted : September 19, 2022
Sponsor:
Collaborators:
Hammersmith Medicines Research
Centessa Pharmaceuticals plc
Information provided by (Responsible Party):
Z Factor Limited

Brief Summary:

This study is composed of two parts. Part A: will test single doses of ZF874 in a double-blind, randomised, placebo-controlled and dose-escalating design (except Group 7, which will be open-label and without placebo). Up to 7 groups of 6-8 healthy volunteers will receive an oral dose of ZF874 or matching placebo (6 active: 2 placebo in Groups 1-6; 6 active in Group 7). The dosing of the first 2 subjects (1 active and 1 placebo) will take place before dosing of the remainder of the group in Groups 1-6, with morning doses given in the fasted state. The dose will be escalated only if the safety and tolerability of the previous highest dose are acceptable, and the plasma concentrations of ZF874 are predicted to remain below the toxicokinetic exposure limit, as determined by the Safety Review Group. Group 7 will consist of 6 subjects, all of whom will receive ZF874 after consuming a standard high-fat breakfast. Dosing of the first 2 subjects before the rest of the group is not required in Group 7, as 6 subjects have already safely received ZF874 at this dose in Group 3 and 12 subjects have already safely received higher doses in Groups 4 and 5.

The dose selected for Part A, Group 7 was chosen as the dose has previously been given to subjects fasted in Group 3, and it was safe and well tolerated, allowing for comparison for the food effect, and higher doses have been tested in Part A with no safety concerns.

Part B: Multiple Ascending Doses in subjects carrying at least one Z mutated alpha-1-antitrypsin (Z-A1AT) allele (PiXZ subjects): Up to 4 groups of up to 5 PiXZ subjects will be enrolled in Part B (Groups 1-4). In Group 1, up to 4 subjects will receive twice daily doses of either ZF874 or placebo on 28 consecutive days. The dose level (dose and dose regimen) selected for Part B Group 1 will be based on review of the available results from Part A. In Groups 2-4, up to 5 PiXZ subjects will receive ZF874 twice daily by mouth for 28 days; no subjects will receive placebo. The dose for Groups 2 - 4 will not exceed the doses already given in Part A.


Condition or disease Intervention/treatment Phase
Alpha1 Anti-Trypsin Deficiency Drug: ZF874 Drug: Placebo Phase 1

Detailed Description:

Part A: Enrolment of up to 54 healthy men and women is planned, in up to 7 groups. Each of the first 6 groups will consist of 8 subjects and the 7th group will consist of 6 subjects. Subjects will receive either one or two oral dose(s) of either ZF874 or placebo, in the fasted state in the first 6 groups. There will be up to 7 dose levels of ZF874. In each of the first 6 groups, two subjects (one placebo, one ZF874) are to be dosed in a double-blind manner at least 23 hours prior to the remainder of the group. In the absence of any safety concerns in the leading subjects, the remaining subjects will be dosed, at intervals of at least 10 minutes. Dosing of the first 2 subjects before the rest of the group is not required in Group 7, as 6 subjects have already safely received ZF874 at this dose in Cohort 3, and 12 subjects have already safely received higher doses in Cohorts 4 and 5. In Group 7, all subjects will receive a single dose of ZF874 by mouth, after consuming a high-fat breakfast. All subjects will be screened in the 28 days before their dose of trial medication. Subjects will be resident on ward from 1 day before their dose (Day -1) until 48 hours after dosing (Day 3). They will return for a follow-up visit 5-7 days after their dose (Day 6-8).

Part B: In Group 1, up to 4 subjects will receive twice daily doses of either ZF874 or placebo on 28 consecutive days (up to 3 active: up to 2 placebo). The dose level (dose and dose regimen) selected for Part B Group 1 will be based on review of the available results from Part A.

In Groups 2-4, up to 5 PiXZ subjects will receive ZF874 twice daily by mouth for 28 days; no subjects will receive placebo. The doses will be selected after reviewing the available safety and pharmacokinetic results from previous groups, but will not exceed the doses already given in Part A.

Subjects will be pre-screened to confirm PiXZ genotype within 84 days before their dose of trial medication. Once their genotype is confirmed, they will be screened in the 28 days before their dose of study medication. Subjects will be resident on the ward from 1 day before their first dose (Day -1) until 1 hour after they receive their second dose (Day 2). They will then attend 6 outpatient visits before returning to the ward and be resident from Day 27 until 24 hours after the final dose (Day 29). They will return for further outpatient visits on Days 36, 43 and 50, and for a follow-up visit 28-30 days after their final dose (Day 56-58).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: This is a double-blind, randomised, placebo-controlled, single ascending and repeat dose trial in healthy subjects and subjects carrying at least one Z-A1AT allele (PiXZ subjects)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Part A Groups 1-6 and Part B Group 1 will be double-blind; Part A Group 7 (food effect) and Part B Groups 2-4 will be open label
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeated Doses of Orally Administered ZF874 in Healthy Volunteers and PiXZ Subjects
Actual Study Start Date : August 3, 2020
Actual Primary Completion Date : September 12, 2022
Actual Study Completion Date : September 12, 2022


Arm Intervention/treatment
Active Comparator: Part A Cohort 1 - ZF874
Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Placebo Comparator: Part A - Placebo to ZF874 - Single Dose
Single oral dose of placebo by mouth in the fasted state
Drug: Placebo
Placebo to ZF874

Active Comparator: Part A Cohort 2 - ZF874
Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part A Cohort 3 - ZF874
Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part A Cohort 4 - ZF874
Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Placebo Comparator: Part A - Placebo to ZF874 - Two Doses
Two doses of placebo (12 h apart) by mouth in the fasted state
Drug: Placebo
Placebo to ZF874

Active Comparator: Part A Cohort 5 - ZF874 - Two Doses
Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part A Cohort 6 - ZF874 - Two Doses
Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part A Cohort 7 - ZF874 - Single Dose
Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part B Cohort 1 - ZF874
Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Placebo Comparator: Part B Cohort 1 - Placebo to ZF874
Two doses of placebo (12 h apart) by mouth daily for 28 days.
Drug: Placebo
Placebo to ZF874

Active Comparator: Part B Cohort 2 - ZF874
Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part B Cohort 3 - ZF874
Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.

Active Comparator: Part B Cohort 4 - ZF874
Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
Drug: ZF874
ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.




Primary Outcome Measures :
  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: Part A: Day 1 to Day 8; Part B: Day 1 to Day 58 ]
    Safety and tolerability


Secondary Outcome Measures :
  1. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 3; Part B: Day 1 to Day 29 ]
    maximum plasma concentration

  2. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 3; Part B: Day 1 to Day 29 ]
    time of maximum plasma concentration

  3. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part B: Day 1 to Day 29 ]
    trough plasma concentration

  4. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 3; Part B: Day 1 to Day 29 ]
    maximum plasma concentration / dose

  5. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 2 ]
    area under the concentration-time curve during the 24 hours post-dose area under curve to 24 hours post-dose

  6. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 3 ]
    area under the concentration-time curve during the 48 hours post-dose area under the concentration-time curve to 48 hours post-dose

  7. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part B: Day 1 to Day 29 ]
    area under the concentration-time curve during the dosing interval

  8. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1 to Day 3; Part B: Day 1 to Day 29 ]
    area under the concentration-time curve to last measurable concentration

  9. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1; Part B: Day 28 ]
    terminal elimination half-life

  10. Pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects and PiXZ subjects [ Time Frame: Part A: Day 1; Part B: Day 28 ]
    terminal rate constant

  11. Food effect on the pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects [ Time Frame: Part A: Day 1 to Day 3 ]
    maximum plasma concentration / dose

  12. Food effect on the pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects [ Time Frame: Part A: Day 1 to Day 3 ]
    area under the concentration-time curve to last measurable concentration

  13. Food effect on the pharmacokinetics of ZF874 and its metabolite ZF857 in healthy subjects [ Time Frame: Part A: Day 1 to Day 3 ]
    area under the concentration-time curve extrapolated to infinite time


Other Outcome Measures:
  1. Pharmacodynamics (Exploratory) [ Time Frame: Part B: Day 1 to Day 58 ]
    Serum levels of Z-mutated alpha-1-antitrypsin (Z-A1AT)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 72 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Part A: healthy Caucasian males or females, aged 18-65 years at the time of consent; Part B: males or females of general good health, aged 18-72 years at the time of consent.
  • Body mass index of 18.0-30.0 kg/m^2 (Part A) and 18.0-35.0 kg/m^2 (Part B).
  • Able to understand the nature of the trial and any hazards of participating in it. Able to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire trial
  • Willing to give written fully informed consent to participate
  • Agree to follow the contraception requirements of the trial
  • Agree not to donate blood or blood products during the study and for up to 3 months after the trial medication
  • Registered with a General Practitioner in the United Kingdom
  • Willing to give written consent to have data entered into The Over-volunteering Prevention System [Part B only]
  • Confirmed genotype with at least one Z alpha-1-antitrypsin allele (PiXZ)

Exclusion Criteria:

  • Woman who is pregnant or lactating, or woman of child-bearing potential who is sexually active and not using a highly effective method of contraception
  • Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer
  • Acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous
  • Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness
  • Creatinine clearance <60 mL/min/1.73m2
  • Active cancer or to be actively on cancer therapy, or diagnosis of cancer (except for Basal Cell Carcinoma, Squamous Cell Carcinoma (fully excised), or Cervical Intra-epithelial Neoplasia in situ) in the 5 years before the first dose of trial medication.
  • Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines
  • Presence or history of severe adverse reaction to any relevant drug
  • During the 28 days before the first dose of trial medication, the use of prescription medicine judged by the investigator to have the potential to influence the results of the study; or during the 7 days before the first dose of trial medication, the use of a herbal supplement or an over-the-counter medicine, with the exception of ibuprofen
  • Receipt of a COVID-19 vaccine within 14 days before the first dose of trial medication; exhibition of symptoms suspected to be related to COVID-19 within 28 days before the first dose of trial medication; or receipt of a positive COVID-19 test during the 28 days before the first dose of trial medication
  • Receipt of an investigational product (including prescription medicines) as part of another clinical trial within 3 months before admission to this study; in the follow-up period of another clinical trial at the time of screening for this study
  • Recent drug or alcohol abuse (within 2 years before screening), or intake of more than 3 units of alcohol daily (for men) or 2 units of alcohol daily (for women); or use of cigarettes or nicotine-containing products during 30 days before the first dose of trial medication until the end of the study
  • Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 90-160 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min
  • Possibility that the volunteer will not cooperate with the requirements of the protocol
  • Evidence of drug abuse on urine testing
  • Positive test for hepatitis B virus, hepatitis C virus or human immunodeficiency virus
  • Loss of more than 400 mL blood during 3 months before the trial, eg as a blood donor
  • Objection by General Practitioner to volunteer entering trial

Part A, Cohort 7 only:

- Vegans, vegetarians, or unwilling to eat a high-fat breakfast containing bacon.

Part B only:

- Undergone liver transplantation


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04443192


Locations
Layout table for location information
United Kingdom
MAC Clinical Research Manchester
Manchester, Greater Manchester, United Kingdom, M13 9NQ
MAC Clinical Research, Barnsley
Barnsley, United Kingdom, S75 3DL
MAC Clinical Research, Leeds
Leeds, United Kingdom, LS10 1DU
Hammersmith Medicines Research
London, United Kingdom, NW10 7EW
MAC Clinical Research, Teesside
Stockton-on-Tees, United Kingdom, TS17 6EW
Sponsors and Collaborators
Z Factor Limited
Hammersmith Medicines Research
Centessa Pharmaceuticals plc
Investigators
Layout table for investigator information
Principal Investigator: Malcolm Boyce, BSc MD FRCP FFPM HMR
Principal Investigator: Giuseppe Fiore, MSc MD MAC Clinical Research
Layout table for additonal information
Responsible Party: Z Factor Limited
ClinicalTrials.gov Identifier: NCT04443192    
Other Study ID Numbers: ZF-0101
First Posted: June 23, 2020    Key Record Dates
Last Update Posted: September 19, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Emphysema
Pathologic Processes